Recent Updates
Recently added Catalysts
RVMD Neutral Sentiment

Revolution Medicines to Participate in April 2025 Investor Conferences

Monday, March 31, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revolution Medicines, Inc. will participate in two upcoming investor conferences in April 2025. The CEO, Dr. Mark A. Goldsmith, is set to take part in the Needham 24th Annual Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum. These events could provide opportunities for the company to engage with investors and promote its oncology therapies aimed at RAS-addicted cancers.
Price reaction · baseline $37.35 (2025-03-28 close) · 1 other RVMD headline(s) in the window, move may be shared
day 0 close
-5.3%
day 1
-10%
day 3 · peak
-12%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in major investor conferences can enhance visibility.
  • Company leadership will engage directly with investors, indicating strong communication.
  • Potential for showcasing advancements in targeted therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
6.7%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
daraxonrasib
Phase 3 · NSCLC (Non-small Cell Lung Cancer)

Full Press Release Details

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences.
Details of the company’s participation are as follows:
Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET
Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines Media & Investor Contact:

Frequently Asked Questions

What company will Mark A. Goldsmith represent at investor conferences?

Mark A. Goldsmith will represent Revolution Medicines, Inc.

When is the Needham Annual Virtual Healthcare Conference?

The conference is on April 7 at 2:15 p.m. ET.

How can I access the event webcasts?

Visit the company's website for live and archived webcasts.

How long will the event replays be available?

Replays will be available for at least 14 days.

What focus does Revolution Medicines have?

The company develops targeted therapies for RAS-addicted cancers.

ShareAdd on Google
Tags: RVMD Viatris Investor Conferences Healthcare investor conferences oncology RAS-addicted cancers Mark A. Goldsmith
Last updated: Mar 31, 2025

Biotech snapshot

Cash runway
$3938M liquidity · $129M/mo burn
~30 mo
Minimal dilution risk
Lead asset
daraxonrasibPhase 3
NSCLC (Non-small Cell Lung Cancer) →

Catalyst track record

+124%
best trade around RVMD's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for RVMD.

See every catalyst's timing & PoA →